I agree, Logan. CellPryme-M is the one that has been under evaluation by prospective parties. In that context, it should garner an outcome before CellPryme-A in terms of a licensing deal. The latter was just brought up by me in context of Scotty mentioning PTX-200. Either way, the CP platform is still in the pipeline, albeit in the background, along with OmniCAR.
Great to see James has a "Corporate Spotlight" interview happening on HC. The more interviews and presentations he does, the better he is getting. PTX-100 for CTCL is definitely the stepping stone to a much bigger market in the oncology space.
Add to My Watchlist
What is My Watchlist?
